The Algerian pharmaceutical group Saidal has reacted to the decision by the Caisse nationale des assurances sociales des travailleurs salariés (CNAS) to suspend the CHIFA card payment system at its pharmacies. Saidal affirmed that its pharmacies operate on solid legal, administrative, and institutional foundations. The group stated that its pharmacies have been licensed by the Ministry of Health since December 27, 1997, in accordance with the laws and regulations in force at the time.

Saidal emphasized that the license issued in 1997 remains fully valid, and the 2018 health law did not explicitly or implicitly provide for its cancellation or expiration. The group cited a decision by the Conseil des participations de l’État, which entrusted Saidal with managing the former company ENDIMED, including its assets and intellectual property, such as the operating license. This decision, dated January 2025, supports Saidal's claim to continue operating its pharmacies.

The CNAS decision to suspend the CHIFA card payment system at Saidal pharmacies took effect on November 15, 2026. This means that patients can no longer purchase medications using their CHIFA cards at Saidal pharmacies, although the decision does not affect other pharmacies that have agreements with CNAS. Saidal announced that it will continue its efforts to clarify the legal and regulatory aspects of its pharmacies' operations and work towards finding solutions to restore the CHIFA card payment system.

Saidal's management expressed its commitment to preserving the rights of social insured individuals and ensuring their continued access to medications and pharmaceutical services. The group stated that it will pursue its activities in strict compliance with the laws and regulations in force, and it is willing to engage in dialogue with relevant stakeholders to guarantee the continuity of its services.

The dispute between Saidal and CNAS centers on the interpretation of the 2018 health law and its implications for the group's pharmacies. Saidal argues that the law does not require the renewal of its operating license, while CNAS appears to hold a different view. The two parties are expected to engage in further discussions to resolve their differences and find a mutually acceptable solution.

The Algerian Ministry of Health has not publicly commented on the dispute between Saidal and CNAS. However, the ministry's role in regulating the pharmaceutical sector and overseeing the activities of pharmacies like Saidal is crucial in resolving the issue. Patients who rely on Saidal pharmacies for their medication needs are anxiously awaiting a resolution to the dispute.

Saidal's reaction to the CNAS decision highlights the complexities of the Algerian healthcare system and the challenges of coordinating between different stakeholders. The outcome of this dispute will have implications for the provision of pharmaceutical services in Algeria and the rights of social insured individuals to access essential medications.

Key points

  • Saidal's pharmacies operate on a valid license issued in 1997, which the group claims remains in force despite the 2018 health law.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.